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Abstract  
Measuring anti-HPV antibody levels is important for surveillance of the immunological 
response to both natural infection and vaccination. Here, an ELISA test for measurement of 
HPV-16L1 antibodies was developed and validated in sera and dried blood spots.  
An in-house ELISA was developed for measuring anti-HPV-16L1 IgA and IgG levels. The 
assay was standardized against WHO international standard serum and validated on serum, 
dried blood spots and cervical liquid based cytology samples from women attending 
colposcopy clinics in Scotland. Antibody avidity index was also measured in serum samples. 
The average HPV 16-L1 specific IgG and IgA levels measured in sera, in women attending a 
routine colposcopy service were 7.3 units/ml and 8.1 units/ml respectively. Significant 
correlations between serum and dried blood spot eluates for both IgG and IgA were observed 
indicating that the latter serve as a credible proxy for antibody levels.  Average IgG Avidity 
Index was 35% (95% CI 25%-45%) suggesting previous, historical challenge with natural 
infection. This ELISA has potential for use in epidemiological and field studies of antibody 
prevalence and if coupled with avidity measurement may be of use in individual case 
monitoring of vaccine responses and failures.  
Keywords: HPV16, Antibody response, Avidity, Dried Blood spots 
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Introduction 
Human Papillomavirus (HPV) infections are very common in the general population with an 
estimated 10-15% prevalence in women of cervical screening age (Crow, 2012). While most 
HPV infections are cleared naturally within 2 years, persistent infection with one of the 
“high-risk” HPVs (HR-HPV) is associated with development of cervical cancer. Two high-
risk types, 16 and 18, are associated with over 70% of cervical cancers (Crow, 2012), which 
has informed prophylactic vaccine design and implementation. In addition, HR-HPV 
infection is strongly associated with development of vaginal, vulval, penile, anal and 
oropharyngeal cancers (Schiffman et al., 2016).   
As only a minority of those infected with HPV develop disease the host immune response is 
clearly important in the regulation and trajectory of the infection. This is also evidenced by 
the fact that immunocompromised individuals are at a greater risk of HPV-associated clinical 
morbidity (Reusser et al., 2015). Antibodies are important for protective immunity against 
HPV infection and neutralising antibodies against the major capsid protein L1 of the virus are 
efficacious against infection with 16/18, which is the rationale behind vaccine design. 
Currently three prophylactic vaccines are licensed for use – the bivalent vaccine which 
confers protection against types 16 and 18, the quadrivalent vaccine which protects against 
16, 18, 6 and 11 and the nonavalent vaccine which protects against HPV 6, 11, 16, 18, 31, 33, 
45, 52 and 58. The rate of seroconversion associated with the licensed vaccines is high, with 
reports of >99% seroconversion in both immunocompetent males and females (Paavonen et 
al., 2007; Van Damme et al., 2015; Villa et al., 2006; Viscidi et al., 2004). Comparatively 
seroconversion as a consequence of natural infection is low with rates of around 50-70% in 
women (Carter et al., 2000) and 4-36% in men (Edelstein et al., 2011), with the average time 
to seroconversion 8-9 months after HPV infection (Carter et al., 2000). In addition, 
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concentrations of anti-HPV16L1 serum antibody associated with natural infection are 
significantly lower than levels generated as a consequence of vaccination (Carter et al., 
2000).  The lower titres of antibodies generated as a consequence of natural infection, when 
compared to those generated by the vaccine, are due to the non-lytic nature of the virus, the 
lack of viraemia and the fact that the epithelia, (the obligate target cells for natural infection) 
are relative sparse with respect to immune effector cells. In comparison as the vaccine is 
delivered by intra-muscular injection(s) more immediate and comprehensive exposure to 
immune effector cells generates high titres of antibodies. 
HPV serology is an essential tool which can provide key insight into the natural history of 
HPV infection particularly given that molecular detection of HPV using nucleic acid 
amplification tests cannot determine previous infection. Furthermore, serological tools 
provide valuable information on the longevity and magnitude of antibody responses to 
vaccination which, through linkage to clinical outcomes, are essential in informing vaccine 
regimens and indications, as well as vaccine failures. Avidity testing can additionally inform 
the quality of antibody response.  However, compared to molecular HPV assays which 
number over 200 (Poljak et al., 2016) there are relatively few HPV serology tests, particularly 
non-proprietary ones. Most serology tests are in-house and not standardised against the WHO 
International standard sera (Bissett et al., 2012). Another challenge in conducting sero-
epidemiology is the practicality of obtaining and processing venous blood, particularly in the 
context of large population based studies. Dried blood spots offer clear operational 
advantages in terms of capture, storage and transport, although to our knowledge only two 
studies have determined the feasibility of this approach (Louie et al., 2018; Waterboer et al., 
2012).  
In light of this, the objectives of the present work were to develop an in house ELISA for the 
measurement of anti-HPV 16-L1 antibodies and perform avidity measurement. The ELISA 
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was calibrated to the WHO international serum standard. Application of the assay in a 
prospective colposcopy population allowed antibody titres in serum and dried blood spots to 
be compared.  
 
Materials and Methods 
Governance 
Ethical approval was obtained for prospective sample collection from Scotland A Research 
Ethics Committee (REF 12/SS/0034).  
Colposcopy cohort from prospective collection- venous blood and cervical liquid based 
cytology (LBC) samples 
The British Association for Cytopathology (BAC) reporting guidelines and the cervical 
intraepithelial neoplasia (CIN) nomenclature were used to classify cytological findings and 
histological outcomes, respectively (Smith and Patnick, 2013). Management of women with 
abnormal cytological results was performed according to guidelines and algorithms 
associated with the United Kingdom National Health Service Cervical Screening Programme 
(NHS CSP), modified for use in the Scottish context (Hirschowitz, 2012; Smith and Patnick, 
2013). Unvaccinated women attending the NHS Lothian Colposcopy clinics after a diagnosis 
of moderate or severe cytological abnormality were recruited to the study. The median age 
was 29 years (21-59 years). Informed consent was obtained from participants for provision of 
a blood and LBC sample at the time of colposcopy visit. Biopsies were performed as 
routinely indicated, and study results did not influence clinical management. A total of 96 
serum samples were collected of which 95 had matching LBC samples (Figure 1).  
Clinical sample collection and processing  
Blood 
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Venous blood was collected and serum and blood spots were prepared. Blood spots were 
prepared using two 75 µl spots on Guthrie spot filter papers. The spots were air dried and 
stored at 4ºC for 24hrs following which blood was eluted using 800µl PBS/0.05% Tween. 
Serum was separated from the remaining blood by centrifugation at 12000g.  
Cervical LBC samples 
Cervical liquid based cytology samples derived  from the clinic were collected into 20ml of 
Preservcyt. Samples were passed through a blunt needle three times to make a uniform cell 
suspension, aliquotted and stored at -20ºC.  
HPV testing of LBC samples 
Genotyping was performed on the LBC samples using the Optiplex HPV Genotyping Kit 
(Diamex GmbH) (Kavanagh et al., 2013) which genotypes 18 high-risk or putatively high-
risk types and 6 low-risk types according to the current IARC classification.   
ELISAs for anti-HPV16 IgG and IgA antibodies in sera and blood spots  
Human International Standard (IS) serum against HPV16 (WHO International Standard 05-
134 HPV 16 antibodies NIBSC code: 05/134) was obtained from The National Institute for 
Biological Standards and Control (NIBSC, South Mimms, UK) and reconstituted to a 
concentration of 10 International Units (IU) of HPV16 L1 specific antibody/ml according to 
instructions (Ferguson et al., 2011). To detect high affinity antibodies which reflect a strong 
immune response, 2-fold dilution(s) from 1 in 1000 to 1 in 64,000 of the IS serum were made 
and used to create a standard curve (Fig 2a). The standard curves were tested 8 times and in 
duplicate on each subsequent plate. All serum samples were tested in duplicate at 1 in 2000 
dilutions.  
For consistency between the amount of total protein in serum and blood spot eluate dilutions, 
we calculated the lowest amount of protein in serum as 3 µg/ml at a 1 in 2000 dilution. 
Therefore, blood spot samples were tested at a protein concentration of 3 µg/well. It should 
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be noted that protein in the blood spot eluates also contained protein from all blood cells as 
well as plasma. 
Successful IgG and IgA binding with the IS sera for HPV16L1 protein (AbCam, Cambridge, 
UK) was obtained when the antigen was used at 50ng/well (500ng/ml) (data not shown,) so 
this concentration was used subsequently for all samples. HPV16L1 protein was diluted in 
100 ul PBS and coated onto ELISA grade 96 well NUNC MaxiSorp®plates (eBiosciences, 
Hatfield UK) by overnight incubation at 4ºC. The wells of the plate were decanted and 
blotted on tissue paper, washed x5 with PBS containing 0.1% Tween20 (wash buffer). ELISA 
buffer (100 µl PBS containing 1% BSA) was added to each well to block non-specific 
binding. IS serum against HPV16L1 protein was pre-absorbed against BSA by diluting to 1 
in 200 with ELISA buffer, incubating overnight at 4 ºC followed by centrifugation at 20,000g 
for 15 min in a benchtop microfuge to remove any complexes. The IS serum was then diluted 
in ELISA buffer, added to wells and incubated for 1h at room temperature. Plates were 
washed as above and 100 µl biotinylated-anti-human IgG (1 in 100,000 dilution), or 
biotinylated-anti-human IgA (1 in 10,000 dilution) both from  Vector Laboratories Ltd 
(Peterborough, UK), were added to the wells and incubated for 1h at room temperature. 
Plates were again washed as above. A 100 µl volume of streptavidin-horseradish peroxidase 
complexes (Vector Laboratories Ltd (Peterborough, UK)) was added to each well and 
incubated for 1h at room temperature before plates were again washed as above.  
Subsequently, a100 µl volume of TMB (SIGMA (Poole, UK) reagent was then added to each 
well and plates incubated at 37ºC for 30 minutes before the colour reaction was stopped with 
1N sulphuric acid. An automated dual filter plate reader was used to measure absorbance at 
450nm/630nm.  
Antibody avidity measurement  
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To determine the avidity index of IgG, we utilised the guanidine hydrochloride method 
(Inouye et al., 1984) that has been used previously in studies of anti-HIV (Chawla et al., 
2007) and anti-HPV IgG antibodies (Dauner et al., 2012) in human serum. Initial experiments 
established that 2M guanidine hydrochloride (GuHCL) treatment gave optimal results in the 
ELISA.  ELISA was performed as described above except GuHCL treatment was performed 
for 15 minutes before addition of biotinylated anti-human IgG.  Avidity index was measured 
as the percentage of IgG (IU/ml) with GuHCL treatment divided by IgG (IU/ml) without 
treatment. GuHCL has been reported as a chemical that disrupts the strength of binding 
between antibody and antigen and in particular does this without disrupting the VLP structure 
of HPV 16-L1. Thus GuHCL was used for the present study 
Statistics 
Analysis was performed using Graphpad Prism™. Data were tested to determine whether 
there was correlation between IgG and IgA in the same samples and between different types 
of samples. A p-value < 0.05 was considered to be statistically significant. 
Results 
Clinical and viral annotation of samples  
Of the 96 women in the study cohort with moderate or severe cytological abnormalities, 5 
(5.2%) had a biopsy which was reported as normal, 1 woman (1.05%) had CIN1, 40 
(41.67%) had CIN2, 43 (45.2%) had CIN3, 2 (2.1%) had high grade cervical glandular 
intraepithelial neoplasia (CGIN) , 1 (1.05%) had small cell cervical carcinoma (SCCC) and 4 
were missing or not definitive (Figure 1).  
HPV genotyping was performed on LBC samples from 95 women (one women had no 
associated LBC sample collected).  A total of 92 (95.7%) women tested positive for any 
HPV, 52 had mono-infections and the remainder of HPV positive women had >=2 infections. 
HPV16/18 were the most common types (48/91, 52%). In total 72 (75.7%) women were 
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currently infected with HPV 16 or a related virus in the alpha species group 9 and 20 women 
were infected with other HR-HPV types (Figure 1). 
Level of anti-HPV16-L1 antibodies in sera 
Anti-HPV16-L1 antibody levels as measure by ELISA in sera from the 96 women were 
measured against standard curves of the IS serum (Figure 2a&b). The average HPV 16-L1 
specific IgG and IgA levels in the colposcopy population was 7.3 units/ml and 8.14 units/ml 
respectively. There was significant correlation between the levels of IgG and IgA anti-
HPV16-L1 antibodies in the sera (two-tailed Spearman r=0.5094, p=<0.0001) (Figure 2c) of 
the women. There was no significant difference between anti-HPV16-L1 IgG or IgA levels 
according to underlying histology (Kruskal Wallis test; no disease IgG versus CIN2+ IgG, 
p=0.7531; no disease IgA versus CIN2+ IgA p=0.9905). 
Level of anti-HPV16-L1 antibodies in blood spot eluates  
All blood spot eluates were tested for total protein concentration and the mean + standard 
error of mean (s.e.m) concentration was 1652+41.78 µg/ml. Data for blood spots are given in 
units of anti-HPV16-L1 specific antibody (IU)/100 mg protein (Figure 3a) calculated against 
standard curves of the IS serum. 
Average IgG level in blood spots in the colposcopy population was 3.94 units/ml and the 
average IgA level was 12.71 units/ml. There was a significant correlation (two-tailed 
Spearman r=0.4900, p=<0.0001) between IgG and IgA antiHPV16L1 antibodies in the blood 
spot eluates (Figure 3b). There were also significant correlations between serum and dried 
blood spot eluates for the levels of IgG, two-tailed Spearman r=0.2815, p=0.0063 (Figure 3c) 
and IgA, two-tailed Spearman r=0.5485, p=<0.0001 (Figure 3d). 
Anti-HPV16-L1 antibody levels according to HPV infection  
To determine whether serum antibody levels reflected current infection, all serum samples 
from women with HPV infection were stratified according to a) having a HPV16 or a 
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phylogenetically related type which resided in the alpha species group 9 or b) having an other 
HPV type, outside the alpha 9 group. Figure 4 shows that, although there was a range in 
levels of anti-HPV16L1 antibody, sera from women currently infected with at least one alpha 
9 type (the majority of whom were HPV 16 positive (n=48/72 alpha 9positive women), 
showed significantly higher values of both IgG (Figure 4a) and IgA (Figure 4b) anti-
HPV16L1 antibodies compared to those infected with other HPV types. 
Avidity index measurement in serum  
Antibody avidity (AI) in sera from 34 women who had IgG values for HPV16 of 75% or 
above (relative to the International Standard serum) (Figure 5) was assessed. The average 
avidity index in the sample set was 34.86 (95% CI- 24.84- 44.88) and of the 34 sera, 33 
showed a significant decrease in antibody levels following GuHCL treatment; the mean + 
s.e.m % decrease was 65.14 + 4.929%. 
 
Discussion 
Efforts at detection of HPV antibodies as a tool to monitor and assess vaccine efficacy have 
increased significantly in recent years. Several assays, designed to measure HPV antibody 
responses in serum are available such as GST- L1 multiplex test (Waterboer et al., 2005), 
cLIA (Wentzensen et al., 2011) and in house ELISAs (Mesher et al., 2016). However, there is 
a lack of harmonization and standardization of these tests which makes it challenging to 
compare data from different studies.  
In the present study a reproducible in-house ELISA was developed using widely available 
reagents which can robustly detect HPV 16 IgG and IgA in serum and blood spots. The assay 
has been calibrated to the international HPV16 serum standard developed by WHO (Pagliusi 
et al., 2006). The ability to use dried blood spots has implications for both low resource and 
primary care settings as they only require taking a droplet of blood and can be transported to 
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the lab at ambient temperatures. A correlation between the levels of IgG and IgA was found 
in serum, blood spot and LBC samples. A strong correlation between anti-HPV16L1 IgG and 
IgA in serum and blood spots was also observed. The present study thus independently 
validates the studies/observations of Waterboer et al (2012), and more recently Louie et al 
(2018) and demonstrates the feasibility of using dried blood spots for surveillance purposes. 
In addition, the  present work we reference to an international standard (which Waterboer et 
al did not incorporate) showed that the ELISA can measure both IgA and IgG effectively. 
Another objective of this study was to use the ELISA to investigate the avidity of IgG 
antibodies which may provide insight into vaccine efficacy during the longitudinal 
monitoring of vaccinated cohorts. 
Avidity is the measurement of the strength of interaction between the specific antibody and 
the antigen it recognises. During the course of an immune response, antibodies of increasing 
avidity for antigen are produced and selected by somatic mutation of the immunoglobulin 
genes in antibody producing B lymphocytes.  Generally, avidity of IgG antibodies increases 
over the 4-6 months following a cleared infection and declines thereafter. Thus a high avidity 
measurement indicates a recent or persistent infection. Natural infection with HPV has been 
associated with low avidity antibodies as demonstrated recently by Louie et al 2018. 
Furthermore, the avidity index (AI) observed in the present study is similar to that observed 
in the study of Scherpenisse et al (2013) who reported around 35% AI associated with natural 
infection and that the AI of vaccine induced antibodies was around 3 times higher.  AI is 
therefore, to an extent a proxy of immunisation-induced antibodies and notably reports that 
AI were similar between a 2-dose and 3-dose regimen supported the rationale for 2-dose 
regimens (Sankaranarayanan et al., 2016). 
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In conclusion, in this study, a standardised ELISA test developed for anti-HPV16L1 
antibodies was validated against the WHO international positive serum standard for HPV16. 
This assay was amenable to both venous blood and dried blood spots. While the sample size 
used for this study is small, this technique has promise for widespread use in epidemiological 
and field studies of antibody prevalence and coupled with the avidity measurement may be of 
use in individual cases for monitoring vaccine responses such as failures. The existence of 
serological assays which are calibrated to the same standards will also facilitate cross-study 
comparison in the future. 
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Figure 1. Underlying pathology of the cervical sample set. Details of samples used within 
the study. CIN- Cervical Intraepithelial Neoplasia, CGIN- Cervical Glandular Intraepithelial 
Neoplasia, SCCC – Small Cell Cervical Cancer, HR-HPV – high –risk Human Papilloma 
virus.  
Figure 2. Measurement of Anti HPV 16 L1 antibodies in sera by ELISA 
(A) Linear regression of ELISA standard curves. Mean (solid lines) and 95% confidence 
intervals (dashed lines); red lines = IgG; black lines = IgA. Plates coated with 50ng/well 
HPV16L1, n=8; r2 for IgG=0.8872; r2 for IgA = 0.9371. OD= optical density. (B) Levels of 
IgG and IgA in serum samples calculated against the IS serum standard. Bars show mean + 
95% confidence interval, n=94. (C) Correlation between levels of anti-HPV16 L1 IgG and 
IgA antibody in sera; n=94; two-tailed Spearman r=0.5248, p=<0.0001. 
 
Figure 3. Measurement of Anti HPV16 L1 antibodies in eluates from dried blood spots. 
(A) IgG and IgA antibody, bars show mean + 95% confidence interval, n=94. (B) Correlation 
between levels of anti-HPV16 L1 IgG and IgA antibody in blood spots; n=94; two-tailed 
Spearman r=0.4900, p=<0.0001 (C) Correlation between levels of anti-HPV16 L1 IgG 
antibody in serum and blood spots; n=95; two-tailed Spearman r=0.2815, p=0.0063. (D) 
Correlation between levels of anti-HPV16 L1 IgA antibody in serum and blood spots; n=95; 
two-tailed Spearman r=0.5485, p=<0.0001. 
Figure 4. Measurement of Anti HPV16 L1 antibodies in sera from women with and 
without infection with HPV 16 (or related types) (A) IgG and (B) IgA levels in serum from 
women with HPV 16 or a virus that resides in the alpha 9 species group, where HPV 16 is 
located (n=72). This is compared to sera from women with unrelated virus types (n=20). Bars 
show 95% confidence interval(s), Mann Whitney Test 
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Figure 5. Measurement of IgG avidityin sera  following treatment with guanidine 
hydrochloride (GuHCl). HPV16L1 binding antibodies in 34 sera with IgG levels >75% of 
the IS serum were compared before and after GuHCl treatment. (A) 33/34 sera showed a 
reduction in avidity after treatment; p<0.001, Wilcoxon signed rank test. (B) Avidity index of 
antibodies in sera; bars show mean + 95% confidence interval. 
 
